Alteration of pharmacokinetics of lepirudin caused by anti-lepirudin antibodies occurring after long-term subcutaneous treatment in a patient with recurrent VTE due to Behcet's disease

Vasa - Journal of Vascular Diseases

Volumn 39, Issue 1, 2010, Pages 103-107

  Linnemann, Birgit ^a   Greinacher, A ^b   Lindhoff Last, E ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Behcet's disease; Budd chiari syndrome; Lepirudin; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; VITAMIN K GROUP;

ADULT; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BEHCET DISEASE; BLEEDING; BLOOD LEVEL; BUDD CHIARI SYNDROME; CASE REPORT; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LONG TERM CARE; LUNG EMBOLISM; REPEAT PROCEDURE; THERAPY EFFECT; VENOUS THROMBOEMBOLISM;

ADULT; ANTIBODIES; ANTICOAGULANTS; BEHCET SYNDROME; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPARIN; HIRUDINS; HUMANS; RECOMBINANT PROTEINS; RECURRENCE; VENOUS THROMBOEMBOLISM;

EID: 77749234087     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526/a000012     Document Type: Article

References (19)

1. Begelman SM, Deitcher SR. Outpatient management of venous thromboembolic disease with subcutaneous lepirudin: a case report. J Thromb Thrombolysis 2002; 13: 183-5.
2. Bounameaux H, Righini M, Perrier A. Venous thromboembolism: Contemporary diagnostic and therapeutic aspects VASA 2008(37) 3: 211-26
3. Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behcet's disease. Curr Opin Rheumatol 2004; 17: 1-8.
4. Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 2000; 96: 2373-2378.
5. Eichler P, Lubenow N, Strobel U, Greinacher A. Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin. Blood 2004; 103: 613-6.
6. Fischer KG, Liebe V, Hudek R, Piazolo L, Haase KK, Borggrefe M, Huhle G. Anti-hirudin antibodies alter pharmacokinetics and harmacodynamics of recombinant hirudin. Thromb Haemost 2003; 89: 973-82.
7. Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost 2008; 99: 819-29.
8. Greinacher A, Eichler P, Albrecht D, Strobel U, Pötzsch B, Eriksson BI. Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. Blood 2003; 101: 2617-9.
9. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003; 108: 2062-5.
10. Huhle G, Liebe V, Hudek R, Heene DL. Anti-r-hirudin antibodies reveal clinical relevance through direct functional inactivation of r-hirudin or prolongation of r-hirudin's plasma halflife. Thromb Haemost 2001; 85: 936-8.
11. Kemkes-Mattes B. Hirudin for prophylaxis and treatment of deep vein thrombosis. Semin Thromb Haemost 2002; 28: 455-8.
12. Lange U, Nowak G, Bucha E. Ecarin chromogenic assay - a new method for quantitative determination of direct thrombin inhibitors like hirudin. Pathophysiol Haemost Thromb 2003; 33: 184-91.
13. Lindhoff-Last E, Piechottka GP, Rabe F, Bauersachs R. Hirudin determination in plasma can be strongly influenced by the prothrombin level. Thromb Res 2000; 100: 55-60.
14. Puurunen M, Lassila R. Successful treatment of mesenterial venous thrombosis with recombinant hirudin - a report of five cases. Thromb Res 2006; 118: 241-5.
15. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. N Engl J Med 1999; 341: 1284-91.
16. Salmela B, Nordin A, Vuoristo M, Mäkisalo H, Numminen K, Lassila R. Budd-Chiari syndrome in a young female with factor V Leiden mutation: successful treatment with lepirudin, a direct thrombin inhibitor. Thromb Res 2008; 121: 769-72.
17. Schiele F, Lindgaerde F, Eriksson H, Bassand JP, Wallmark A, Hansson PO, Grollier G, Sjo M, Moia M, Camez A, Smyth V, Walker M. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre pros-pective dose-ranging randomized trial. International Multicentre Hirudin Study Group. Thromb Haemost 1997; 77: 834-8.
18. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133: 340S-380S.
19. Yusuf S for the Direct Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary snydromes: principal results of a meta-analysis based on individual's patients' data. Lancet 2002; 359: 294-302.